- Oops!Something went wrong.Please try again later.
DGAP-News: Biotest AG / Key word(s): Study results
Cytotect CP(R) Biotest activates immune cells that are crucial to control Cytomegalovirus
A new scientific publication by Deml and colleagues indicates that Biotest's CMV hyperimmunoglobulin product Cytotect CP(R) Biotest has various beneficial effects on patients suffering from CMV infection. The study, which was supported by Biotest AG, analysed CMV-positive and CMV-negative blood donors and their immune response towards CMV.
The new data shows that Cytotect CP(R) Biotest is able to activate different immune cells. This includes also the activation of cytotoxic T lymphocytes by CMV, which may happen via an immunological process termed cross-presentation. In this study, the effect was more prominent when Cytotect CP(R) Biotest was used and - importantly - this was also observed in presence of immunosuppressive drugs, which are part of the standard treatment regimen of patients after transplantation.
"Altogether, this study demonstrates that, in addition to the transfer of passive humoral immunity, the use of Cytotect CP(R) Biotest in transplantation might promote a stronger and faster cellular response to CMV infection and thus contribute to CMV prophylaxis." states Dr Christian Hüber, Senior Manager Corporate Medical Affairs from Biotest. Interestingly, the new data are well in line with new findings from researchers in the United Kingdom who have recently shown that Cytotect CP(R) Biotest is able to promote the activation of natural killer cells via a mechanism called antibody-dependent cellular cytotoxicity. Although they observed such an effect also with experimental monoclonal antibodies, it was most prominent when the commercially available and approved product Cytotect CP(R) Biotest was used in their experiments.
Biotest AG welcomes these new data and considers to support additional studies looking into the mode of action of Cytotect CP(R) Biotest as well as other hyperimmunoglobulin products.
About Cytotect CP(R) Biotest
Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
 Vlahava, V.M., et al., Monoclonal antibodies targeting nonstructural viral antigens can activate ADCC against human cytomegalovirus. J Clin Invest, 2021. 131(4).
16.11.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
0 61 03 - 8 01-0
0 61 03 - 8 01-150
Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID:
End of News
DGAP News Service